Sharekhan recommended Hold rating on Zydus Wellness with a target price of Rs 1610 in its research report dated November 13, 2019.
Sharekhan's research report on Zydus Wellness
Post the acquisition of Heinz portfolio, Q1 and Q4 are the best quarters for Zydus Wellness (ZWL) due to higher sales of Glucon D and Nycil during these quarters; seasonality is spread in the ratio of 70:30 between Q1/Q4 and Q2/Q3 of any fiscal for Heinz portfolio. After consolidation of Heinz portfolio, revenue growth was muted at 3.6% on like-to-like basis due to lower sales of by-products such as ghee and trading of milk; excluding by-products, revenue grew by ~9% led by steady performance of some key brands. Profitability was affected due to a change in revenue mix (lesser contribution from high margin products) and higher input prices (including milk).
We have reduced our earnings estimates for FY2020 and FY2021 to factor in seasonality in business and maintain our Hold rating with a revised PT of Rs. 1,610.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.LIVE NOW... Video series on How to Double Your Monthly Income... where Rahul Shah, Ex-Swiss Investment Banker and one of India's leading experts on wealth building, reveals his secret strategies for the first time ever. Register here to watch it for FREE.